| Drug Name |
Azacitidine |
| Drug ID |
BADD_D00194 |
| Description |
A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. |
| Indications and Usage |
For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia. |
| Marketing Status |
Prescription |
| ATC Code |
L01BC07 |
| DrugBank ID |
DB00928
|
| KEGG ID |
D03021
|
| MeSH ID |
D001374
|
| PubChem ID |
9444
|
| TTD Drug ID |
D09FAZ
|
| NDC Product Code |
43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029 |
| Synonyms |
Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816 |
